Jessica Moore | Vice President, Investor Relations |
Joaquin Duato | Chief Executive Officer |
Joe Wolk | Chief Financial Officer |
Terence Flynn | Morgan Stanley |
Larry Biegelsen | Wells Fargo |
Chris Schott | JPMorgan |
Joanne Wuensch | Citi |
Louise Chen | Cantor Fitzgerald |
Josh Jennings | Cowen |
Chris Shibutani | Goldman Sachs |
David Risinger | SVB Securities |
Good morning and welcome to Johnson & Johnson’s Second Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference call over to Johnson & Johnson.
You may begin.
Please note that today’s meeting may include forward-looking statements relating to, among other things, the company’s future financial performance, product development, market position and business strategy and the anticipated separation of the company’s consumer health business.
You are cautioned not to rely on these statements, which are based on current expectations of future events using the information available as of today’s date and are subject to certain risks and uncertainties that may cause the company’s actual results to differ materially from those projected.